Listen "FDA Approval Updates Galore"
Episode Synopsis
Lots of FDA approval updates to discuss from the past few weeks:
-Zongertinib gets approved in 1st line setting for ERBB2 TKD mutated metastatic NSLCLC
-Encorafenib approval with cetuximab + FOLFOX
-Teclistamab + Daratumumab approved in 2nd line setting for r/r multiple myeloma
-Acalabrutinib + venetoclax (but NOT acalabrutinib + venetoclax + obinutuzumab) is approved for CLL
Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm
-Zongertinib gets approved in 1st line setting for ERBB2 TKD mutated metastatic NSLCLC
-Encorafenib approval with cetuximab + FOLFOX
-Teclistamab + Daratumumab approved in 2nd line setting for r/r multiple myeloma
-Acalabrutinib + venetoclax (but NOT acalabrutinib + venetoclax + obinutuzumab) is approved for CLL
Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm
More episodes of the podcast OncoPharm
Iberdomide
20/08/2026
Kidney Cancer in a Nutshell
13/08/2026
Small Cell Lung Cancer and CINV Updates
06/08/2026
Zidesamtinib & PPIs in Pacific
30/07/2026
Gedatolisib et al
23/07/2026
Endurance Part 2
16/07/2026
A Decade of CAR-T, Ocra-T, & POLARGO
09/07/2026
Breast Cancer Updates and T-Cell Stemness
25/06/2026
ASCO '26
11/06/2026
